ArticleHypertension research : official journal of the Japanese Society of Hypertension2026
Angiotensin III induces disruption of blood-brain barrier integrity in vitro in bEnd.3 brain endothelial cells.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MFSD2A in health and disease: lysolipid transport, barrier physiology, and translational boundaries.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is well-known to cause disruption of the blood-brain barrier (BBB). Angiotensin (Ang) II is one of the major mechanistic factors leading to impairment of BBB integrity under hypertensive states. However, the impact of Ang III, produced by conversion from Ang II, on the BBB remains to be elucidated. Therefore, this study was aimed to evaluate the effect of Ang III on an in vitro model of BBB using mouse brain microvascular endothelial cell line (bEnd.3). Following exposure of bEnd.3 cells to Ang III at doses ranging between 10 and 1000 nM for 6, 12, and 24 h, cell viability, transendothelial electrical resistance (TEER), and permeability of sodium fluorescein (NaFl) tracer were determined. The expression of claudin-5, caveolin-1 (Cav-1) and major facilitator superfamily domain-containing protein 2a (Mfsd2a) were assessed using immunofluorescence and western blotting. Overall decreases in cell viability and TEER and increases in NaFl permeability were observed at all time points following Ang III administration at various doses (P < 0.05, P < 0.01). 12-h treatment of Ang III at 25, 50, and 500 nM doses decreased claudin-5 but increased Cav-1 expression, while Mfsd2a expression decreased significantly by 500 nm Ang III (P < 0.0001). Our data demonstrate for the first time that Ang III leads to alterations in transport of substances across the BBB through both paracellular and transcellular pathways when administered at specific concentrations and durations in in vitro setting which suggests that it may potentially play a role in the disruption of BBB integrity under hypertensive conditions.
Indexed as
Identifiers
41136598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.